p53 mutations, methylation and genomic instability in the progression of chronic myeloid leukaemia

Leukemia and Lymphoma

Volumn 26, Issue 3-4, 1997, Pages 211-226

  Guinn, Barbara Ann ^a   Mills, Ken I ^b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Chronic myeloid leukemia; Genomic instability; Methylation; p53

Indexed keywords

BCR ABL PROTEIN; CALCITONIN; MUTANT PROTEIN; PROTEIN P53;

CANCER GROWTH; CELL ONCOGENE; CHRONIC MYELOID LEUKEMIA; CPG ISLAND; DISEASE COURSE; DNA CONFORMATION; DNA METHYLATION; DNA REPAIR; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENETIC STABILITY; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; REVIEW; TRANSACTIVATION; TUMOR SUPPRESSOR GENE; VIRUS ONCOGENE;

EID: 0030796486     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709051771     Document Type: Review

References (93)

1. Fearon, E. R. and Vogelstein, B. (1990). A genetic model for colorectal tumorigenesis. Cell, 61, 759-767.
2. Brown, W. M. C. and Doll, R. (1965). Mortality from cancer and other causes after radiotherapy for alkylosing spondylitis. British Medical Journal, 2, 1327-1332.
3. Marshall, C. J. and Rigby, P. W. J. (1984). Viral and cellular genes involved in oncogenesis. Cancer Surveys, 3, 183-214.
4. Farrow, A., Jacobs, A. and West, R. R. (1989). Myelodysplasia, chemical exposure and other environmental factors. Leukemia. 3, 33-35.
5. Yuasa, Y., Srivastava, S. K., Dunn, C. Y., Rhim, J. S., Reddy, E. P. and Aaronson, S. A (1983). Acquisition of transforming properties by alternative point mutations within c-bas/has human proto-oncogene. Nature, 303, 775-779.
6. Dalla-Favera, R., Bregm, M., Erikson, J., Patterson, D., Gallo, R. C. and Croce, C. M. (1982). Human c-myc one gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proceedings of the National Academy of Science USA, 79, 7824-7827.
7. Sap, J., Munoz, A., Schmitt, J., Stinneneberg, H. and Vennstrom, B. (1989). Repression of transcription mediated at a thyroid hormone response element by the v-erb-A oncogene product. Nature, 340, 242-244.
8. Lane, D. P. and Crawford, L. V. (1979). T-antigen is bound to a host protein in SV40-transformed cells. Nature, 278, 261-263.
9. DeCaprio, J. A., Ludlow, J W., Figge, J., Shew, J. Y., Huang, C. M., Lee, W. H., Marsilio, E., Paucha, E. and Livingston, D. M. (1988). SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell, 54, 275-283
10. Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K., Bigner, S. H., Davidson, N., Baylin. S., Devilee, P., Glover, T., Collins, F. S., Weston, A., Modali, R., Harris, C. and Vogelstem. B. (1989). Mutations in the p53 gene occur in diverse tumour types. Nature, 342, 705-708.
11. Linzer, D. I. H. and Levme, A. J. (1979). Characterization of a 54K dalton cellular SV40 tumour antigen present in SV40-transformed cells and unmfected embryonal carcinoma cells. Cell, 17, 43-52.
12. DeLeo, A. B., Jay, G., Appella, E., Dubois, G. C., Law, L. W. and Old, L. J. (1979). Detection of transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proceedings of the National Academy of Science USA, 76, 2420-2424.
13. Eccles, D., Cranston, G., Steel, C M., Nakamura, Y. and Leonard, R (1990). Allele losses on chromosome 17 in human epithelial ovarian cancer. Oncogene, 5, 1599-1601.
14. Mackay, J., Steel, C. M., Elder, P. A., Forrest, A. P. and Evans, H. J. (1988). Allele loss on the short arm of chromosome 17 in breast cancers Lancet, 2, 1384-1385.
15. Vogelstein, B., Fearon, E. R., Kern, S. E., Hamilton, S. R., Preisinger, A. C., Nakamura, Y. and White, R. (1989). Allelotype of colorectal carcinomas. Science, 244, 207-211
16. Isobe, M., Emmanuel, B. S., Givol, D., Oren, M. and Croce, C. M (1986). Localisation of gene for human p53 tumour antigen to bank 17pl3. Nature, 320, 84-85.
17. Soussi, T., de Fromentel, C. C., Mechali, M., May, P. and Kress, M. (1987). Cloning and characterization of a cDNA from Xenopus laevis coding for a protein homologous to human and murine p53. Oncogene, 1, 71-78.
18. Krawczak, M., Smith-Sorenscn, B., Schmidtke, J., Kakkar, W, Cooper, D. N. and Hovig. E. (1995). Somatic spectrum of cancer-associated single basepair substitutions in the TP53 gene is determined mainly by endogenous mechanisms of mutation and by selection. Human Mutation, 5, 48-57.
19. Wada, H., Asada, M., Nakazawa, S., Itoh, H., Kobayashi, Y., Inoue, T., Fukumuro, K., Chan, L. C., Sugita, K., Hanada, R., Akuta, N., Kobayahi, N. and Mizutani, S. (1994). Clonal expansion of p53 mutant cells in leukemia progression in vitro. Leukemia, 8, 53-59.
20. Nakai, H., Misawa, S., Taniwaki, M., Horiike, S., Takashima, T., Seriu, T., Nakagawa, H., Fujii, H., Shimazaki. C., Maruo, N., Akaogi, T., Uike, N., Abe, T. and Kashima, K. (1994). Prognostic significance of loss of a chromosome 17p and p53 gene mutations in blast crisis of chronic myelogenous leukaemia. British Journal of Haematology, 87, 425-427.
21. Nakai, H., Misawa, S., Toguchida, J., Yandell, D. W. and Ishizaki, K. (1992). Frequent p53 gene mutations in blast crisis of chrome myelogenous leukemia, especially in myeloid crisis harboring loss of chromosome 17p. Cancer Research, 52, 6588-6593.
22. Borgstrom, G. H., Vuopio, P. and de la Chapelle, A. (1982). Abnormalities of chromosome 17 in myeloproliferative disorders. Cancer Generics & Cytogenetics,5, 123-135.
23. Rodriguez, M. A., Ford, R. J., Goodacre, A., Selvanayagam, P., Cabanillas, F. and Deisseroth, A. B. (1991). Chromosome 17p and p53 changes in lymphoma. British Journal of Haematology, 79, 575-582.
24. Nakai, H., Misawa, S., Horiike, S., Meekawa, T., Kashima, K. and Ishizaki, K. (1995). Hemizygous expression of the wild-type p53 allele may confer a selective growth advantage before complete inactivation of the p53 gene in the progression of chronic myelogenous leukaemia. British Journal of Haematology, 90, 147-155.
25. Knudson, A. G. (1971). Mutation and cancer: Statistical study of retinoblastoma. Proceedings of the National Academy of Sciences USA, 68, 820-823.
26. Lane, D. P. (1992). p53, guardian of the genome. Nature, 358, 15-16.
27. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B. and Craig, R. W. (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Research, 51, 6304-6311.
28. Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L. and Wyllie, A. H. (1993). Thymocyte apoptosis induced by p53-dependent and independent pathways Nature, 362, 786-787.
29. Yin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C. and Wahl, G M. (1992). Wild type p53 restores cell cycle and inhibits gene amplification in cells with mutant p53 alleles. Cell, 70, 937-948.
30. Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T. and Tlasty, T. D. (1992). Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70, 923-935.
31. Hartwell, L. (1992). Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell, 71, 543-546.
32. Carder. P. J., Cripps, K. J., Morris, R., Collins, S., White, S., Bird, C. C. and Wyllie, A. H. (1995). Mutation of the p53 gene precedes aneuploid clonal divergence in colorectal carcinoma. British Journal of Cancer, 71, 215-218.
33. Wada, C., Shionoya, S., Fujino, Y., Tokuhiro, T., Akahoshi, T., Uchida, T. and Ohtani. H. (1994). Genomic instability of microsatellite repeats and its association with the evolution of chronic myelogenous leukemia Blood, 83, 3449-3456.
34. Fialkow, P. J., Jacobson, R. J. and Papayannopoulou, T. (1977) Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. American Journal of Medicine, 63, 125-130
35. Silver, R. T. (1990). Chronic myeloid leukemia. A perspective of the clinical and biological issues of the chronic phase. Hematology and Oncology Clinics of North America, 4, 319-323.
36. Rowley, J. D. and Testa, J R. (1982). Chromosomal abnormalities in malignant haematalogic diseases. Advances in Cancer Research, 36, 103-148.
37. Nowell, P. C and Hungerford, D. A. (1960). Chromosome studies on normal and leukemic human leukocytes. Journal of the U.S. National Cancer Institute, 25, 85-93.
38. Caspersson, T., Gahrton, G., Lindsten, J and Zech, L. (1970). Identification of the Philadelphia chromosome as a number 22 by quinacrine mustard fluorescence analysis. Experimental Cell Research, 63, 238-240.
39. Rowley, J. D. (1973). Letter A new consistent chromosome abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature, 243, 290-293.
40. Pendergast, A. M., Muller, A. J., Havlik, M. H., Maru. Y and Witte, O. N. (1991). BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phoshotyrosine-dependeny manner. Cell, 66, 161-171.
41. Muller, A. J., Pendergast, A. M., Havlik, M H., Puil, L., Pawson, T. and Witte, O. N. (1992). A limited set of SH2 domains binds BCR through a high affinity phosphotyrosine-independent interaction. Molecular & Cellular Biology, 12, 5087-5093.
42. Pawson, T. (1988). Non-catalytic domains of cytoplasmic protein-tyrosine kinases: regulatory elements in signal transduction. Oncogene, 3, 491-195.
43. Rac. Nature, 351, 400-402.
44. Maru, Y. M. and Witte, O N. (1991). The BCR gene encodes a novel serine/threonine kinase activity within a single exon. Cell, 67, 459-468.
45. Scott, M. L., Van Etten, R. A., Daley, G. Q. and Baltimore, D. (1991). v-abl causes hemopoietic disease distinct from that caused by bcr-abl. Proceedings of the National Academy of Sciences USA, 88, 6506-6510.
46. Pendergast, A. M., Muller, A J., Havlik, M. H., Clark, R., McCormick, F. and Witte, O. N. (1991). Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor. Proceedings of the National Academy of Sciences USA, 88, 5927-5931.
47. Kaye, F. J., Najfeld, V., Singer, J., Cuttner, J. and Fialkow, P. J. (1984). Confirming evidence for the clonal development and stem cell origin of Philadelphia chromosome-negative chronic myelogenous leukemia American Journal of Hematology, 17, 93-96.
48. Lisker, F., Casas. L., Mutchinick, O., Perez-Chavez, F and Labardim, J. (1980). Late-appearing Philadelphia chromosome in two patients with chronic myelogenous leukemia. Blood, 56, 812-814.
49. Frassoni, F., Repetto, M., Podesta, M., Piaggo, G., Raffo, M. R., Sessarego, M., Bacigalupo, A. and Marmont, A. M. (1986). Competitive survival/proliferation of normal and Phlpositive haemopoietic cells. British Journal of Haematology, 63, 135-141.
50. Sokal, J. E., Gomez, G. A., Baccarani. M., Tura, S., Clarkson, B. D., Cervantes, F, Rozman. C., Carbonell. F., Anger, B., Heimpel, H., Nissen, N. I. and Robertson, J. E. (1988). Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. Blood, 72, 294-298.
51. Mitelman, F. (1993). The cytogenetic scenario of chronic myeloid leukaemia. Leukemia and Lymphoma, 11, 11-15.
52. Sawyers, C. L. (1993). The role of myc in transformation by BCR-ABL. Leukemia and Lymphoma, 11,45-46.
53. Mori, N., Wada, M., Yokota, J., Terada. M., Okada, M., Teramura, M., Masuda, M., Hoshino, S., Motoji, T., Oshimi. K. and Mizuguchi, H. (1992). Mutations of the p53 tumour suppressor gene in haematological neoplasms. British Journal of Haematology. 81, 235-240.
54. Fenaux, P., Preudhomme, C., Quiquandon, I., Jonveux, P., Lai, J. L., Vanrumbeke, M., Loucheux-Lefebvre. M. H., Bauters, F., Berger, R. and Kerckaert, J. P. (1992). Mutations of the p53 gene in acute myeloid leukaemia. British Journal of Haematology, 80, 178-183.
55. Jonveux, P., Fenaux, P., Quiquandon, I., Pignon, J M., Lai, J. L., Loucheux-Lefebvre, M. H., Goossens, M., Bauters, F. and Berger, R. (1991). Mutations in the p53 gene in myelodysplastic syndromes Oncogene, 6, 2243-2247.
56. Ahuja, H., Bar-Eli, M., Advani, S. H., Benchimol, S. and Cline, M. J. (1989). Alterations in the p53 gene and the clonal evolution of the blast crisis in chronic myelocytic leukemia. Proceedings of the National Academy of Sciences USA, 86, 6783-6787.
57. Ahuja, H., Bar-Eli, M., Arlin, Z., Advani, S., Allen, S. L., Goldman, J., Snyder, D., Foti. A. and Cline, M. (1991). The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. Journal of Clinical Investigation. 87, 2042-2047.
58. Mashal, R., Shtalnd, M., Talpaz, M., Kantarjian, H., Smith, L., Beran, M., Cork, A., Trujillo. J., Gutterman, J. and Deisseroth, A. (1990). Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia. Blood, 75, 180-189.
59. Foti, A., Ahuja, H. G., Alien, S. L., Koduru, P., Schuster, M. W., Schulman, P., Bar-Eli, M. and Cline, M. J. (1991). Correlation between molecular and clinical events in the evolution of chronic myelocytic leukemia in blast crisis. Blood, 77, 2441-2444.
60. Guinn, B. A., Smith. M., Padua, R. A., Burnett, A. K and Mills, K. I. (1995). Changing p53 mutations with the evolution of chronic myeloid leukaemia from the chronic phase to blast crisis. Leukemia Research 19, 519-525.
61. Feinstein, E., Cimino. C., Gale, R. P., Alimena, G., Berthier, R., KUhi. K., Goldman, J., Zaccaria, A., Berrebi, A. and Canaani, E. (1991). p53 in chronic myelogenous leukemia in acute phase. Proceedings of the National Academy of Science, USA, 88, 6293-6297.
62. Foti, A. and Cline, M. J. (1994). Sequential relapses of blastic crisis may involve different clones of cells with different molecular abnormalities. British Journal of Haematology, 87, 627-630.
63. Kurosawa, M., Okabe, M., Kumeda, Y. and Miyazaki, T. (1994). p53 mutation in the chronic phase was not detected in the myeloid crisis of a chronic myelocytic leukemia case Blood. 83, 2750-2752.
64. Laneuville. P., Sun. G., Timm, M. and Vekemans, M. (1992) Clonal evolution in a myeloid cell line transformed to interleukin-3 independent growth by retroviral transduction and expression of p210bcr/abl Blood, 80, 1788-1797
65. Lin, S. Y. and Riggs, A. D. (1972). Lac operator analogues: bromodeoxyuridine substitution in the lac operator affects the rate of dissociation of the lac repressor. Proceedings of the National Academy Science USA. 69, 2574-2576.
66. Fischer, E. F and Caruthers, M. H. (1979). Studies on gene control regions XII The functional significance of a Lac operator constitutive mutation Nucleic Acids Research. 7, 401-416.
67. Smith, H. O. (1979). Nucleotide sequence specificity of restriction endonucleases. Science, 205, 455-462
68. Pollack, Y., Stem, R., Razin, H. and Cedar, H (1980). Methylation of foreign DNA sequences in eukaryotic cells. Proceedings of the National Academy Science USA, 11, 6463-6467.
69. Vovis, G. F., Horiuchi, K. and Zinder, N. D. (1974). Kinetics of methylation of DNA by restriction endonuclease from Escheriehia coli B. Proceedings of the National Academy Science USA, 71, 3810-3813.
70. Bird, A. P. (1978). Use of restriction enzymes to study eukaryotic DNA methylation: II. The symmetry of methylated sites supports, semi-conservative copying of the methylation pattern. Journal of Molecular Biology, 118, 49-60.
71. Bird, A. P (1986). CpG-rich islands and the function of DNA methylation. Nature (London) 321, 209-213.
72. Hillyard, C. J., Oscier, D. G., Foa, R., Catovsky, D. and Goldman, J M. (1979). Immunoreactive calcitonin in leukaemia. British Medical Journal, 2, 1392-1393.
73. Foa, R., Oscier, D. G., Hillyard, C. J., Incarbone, E., Maclntyre, I. and Goldman, J. M. (1982). Production of immunoreactive calcitonin by myeloid leukaemia cells. British Journal of Haematology, 50, 215-223.
74. Koeppler, H., Pfleuger, K. H., Knapp, W. and Havemann, K. (1987). Establishment of three permanent human leukaemia cell lines producing immunoreactive calcitonin. British Journal of Haematology, 65, 405-409.
75. Foa. P., Ortolani, S., Pogliani, E. M., Lurlo, A., Gualdoni, A., Maiolo, A. T. and Polli, E. E. (1990). Immunoreactive calcitonin: a tumor marker for myelogenous leukemias. International Journal of Biological Markers, 5, 27-30.
76. Riggs, A. D. and Jones, P. A. (1983). 5-Methylcytosine, gene regulation and cancer. Advances in Cancer Research, 40, 1-30.
77. Femberg, A. P. and Vogelstein, B. (1983). Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature, 301, 89-92.
78. Baylin, S. B., Hoppener, J. W M., de Bustros, A., Steenbergh, P. H., Lips, C. J. M and Nelkin, B. D. (1986). DNA methylation patterns of the calcitonin gene in human lung cancers and lymphomas. Cancer Research. 46, 2917-2922.
79. Baylin, S. B., Fearon, E. R., Vogelstein, B., de Bustros, A., Sharkis, S. J., Burke, P. J., Staal, S. P and Nelkin, B. D. (1987). Hypermethylation of the 5′ region of the calcitonin gene is a property of human lymphoid and acute myeloid malignancies. Blood, 70, 412-17.
80. Malinen, T., Palotie, A., Pakkala, S., Peltonen, L., Ruutu. T. and Jansson, S.-E. (1991). Acceleration of chronic myeloid leukemia correlates with calcitonin gene hypermethylation. Blood, 77, 2435-2440.
81. Mills, K. I., Guinn, B. A., Walsh, V. and Burnett, A. K (1996). Calcitonin methylation, p53 mutations and disease progression in CML. Leukemia Research, 20, 771-775.
82. Ohyashiki, J. H., Ohyashiki, K., Kawakubo, T., Tauchi, T., Shimamoto, T. and Toyama, K. (1993). The methylation status of the major breakpoint cluster region in human leukemia cells, including Philadelphia chromosome-positive cells, is linked to the lineage of hematopoietic cells. Leukemia, 7, 801-807
83. Lite, C. E., Goldfarb, A. N., Strickler, J G. and Brunning, R. D. (1990). Presence of lineage-specific hypomethylated sites in the major breakpoint cluster region. Cancer Research, 50, 4984-4990.
84. Litz, C. E., McClure, J. S., Coad, J. E., Goldfarb, A. N. and Brunning, R. D. (1992). Methylation status of the major breakpoint cluster region in Philadelphia chromosome negative leukemias. Leukemia, 6, 35-41
85. Mills, K. I., Sproul, A. M. and Burnett, A. K. (1993). Methylation of the major breakpoint cluster region (M-BCR) in Philadelphia-positive CML. Leukemia, 7, 707-711.
86. Ohtsuki, T., Nishitani, K., Hatamochi, A., Yawata, Y. and Namba, M. (1991). Analysis of methylation in the c-MYC gene in five human myeloma cell lines. British Journal of Haematology, 77, 172-179.
87. Huffman, R. M. (1990). Unbalanced transmethylation and the perturbation of the differentiated state leading to cancer. Bioessays, 12, 163-166.
88. Lewis, J. and Bird, A. (1991). DNA methylation and chromatin structure. FEBS Letters, 285, 155-159.
89. Smith, S. S. (1991). DNA methylation in eukaryotic chromosome stability. Molecular Carcinogenesis, 4, 91-92.
90. Pogribny, I. P, Basnakian, A. G., Miller, B. J., Lopatina, N. G., Poirier, L. A. and James, S. J. 0995). Breaks in genomic DNA and within the p53 gene are associated with hypomethylation in livers of folate/methyl-deficient rats. Cancer Research, 55, 1894-1901.
91. Cariello, N. F., Cui, L., Beroud, C. and Soussi, T. (1994). Database and software for the analysis of mutations in the human p53 gene. Cancer Research, 54, 4454-1460.
92. Zion, M., Ben-Yehuda, D., Avraham, A., Cohen, O., Wetzler, M., Melloul, D. and Ben-Nenah, Y. (1994). Progressive de novo DNA methylation at the BCR-ABL locus in the course of chronic myelogenous leukemia. Proceedings of the National Academy of Sciences, USA, 91, 10722-10726.
93. Nelkin, B. D., Przepiorka, D., Burke. P. J., Thomas, E. D. and Baylin, S. B. (1991). Abnormal methylation of the calcitonin gene marks progression of chronic myelogenous leukemia. Stood, 77, 2431-2434.